Ocular Therapeutix receives FDA nod for SOL-R registrational study of Axpaxli
New Study Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory process for Axpaxli, according to a press release. The FDA…